Key regions: United States, Europe, Brazil, Japan, United Kingdom
Bronchodilator drugs are widely used in the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). Central America is a region that has seen a surge in the demand for these drugs in recent years.
Customer preferences: The growing prevalence of respiratory diseases in Central America has led to an increase in the demand for bronchodilator drugs. Patients suffering from asthma and COPD prefer these drugs as they provide quick relief from symptoms such as shortness of breath, wheezing, and chest tightness.
Trends in the market: One of the major trends in the bronchodilator drugs market in Central America is the increasing adoption of combination therapies. Combination therapies involve the use of two or more drugs in a single inhaler device. These therapies are preferred by patients as they provide better symptom control and are more convenient to use. Another trend is the shift towards long-acting bronchodilators, which provide sustained relief from symptoms and have a longer duration of action compared to short-acting bronchodilators.
Local special circumstances: The bronchodilator drugs market in Central America is characterized by the presence of both multinational and local pharmaceutical companies. Multinational companies dominate the market, but local companies are gaining traction by offering lower-priced generic versions of branded drugs. Moreover, the lack of healthcare infrastructure and limited access to healthcare services in some parts of the region has resulted in patients relying heavily on over-the-counter drugs.
Underlying macroeconomic factors: The growing prevalence of respiratory diseases in Central America can be attributed to several factors such as air pollution, smoking, and genetic predisposition. The region has also seen an increase in the aging population, which is more susceptible to respiratory diseases. The improving economic conditions in the region have led to an increase in healthcare spending, which has further fueled the demand for bronchodilator drugs. However, the high cost of branded drugs and the lack of insurance coverage for these drugs in some countries has limited their accessibility to certain segments of the population.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
